These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 25959588)

  • 1. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
    Shao H; Chung J; Lee K; Balaj L; Min C; Carter BS; Hochberg FH; Breakefield XO; Lee H; Weissleder R
    Nat Commun; 2015 May; 6():6999. PubMed ID: 25959588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
    Sorribes IC; Handelman SK; Jain HV
    J R Soc Interface; 2020 Jan; 17(162):20190722. PubMed ID: 31964274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
    Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
    Chen H; Li X; Li W; Zheng H
    J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
    Watanabe R; Nakasu Y; Tashiro H; Mitsuya K; Ito I; Nakasu S; Nakajima T
    Brain Tumor Pathol; 2011 Apr; 28(2):127-35. PubMed ID: 21331613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
    Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
    Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
    Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
    Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
    PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.